Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository (HS PROGRESS)

Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characterize the clinical and biological features of HS. The results of this research will provide a basis for the development of an HS clinical classification system and identification of potential treatments for HS.

Study Overview

• Status: Recruiting
• Conditions: Hidradenitis Suppurativa

• Study Type: Observational
• Enrollment (Estimated): 3000

Contacts and Locations

• Study Contact: Name: Kaelin Chatterley; Phone Number: 415-961-3786; Email: hsprogress@ucsf.edu

Study Locations

• United States
  • California
    • San Francisco, California, United States, 94115
      • Recruiting
      • University of California San Francisco
      • Principal Investigator: Haley B Naik, MD, MHSc, FAAD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 10 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

HS Patients

Description

Inclusion Criteria:

1. Male or female ≥ 10 years of age
2. Diagnosis of HS by a dermatologist or practitioner experienced in making a diagnosis of HS
3. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.

Exclusion Criteria:

1. Inability to give informed consent or unavailability of a parent/guardian who is able and willing to give informed consent.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Objective	The primary aim of this study is to identify clinical and biologic characteristics of hidradenitis suppurativa.	2019-2035

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Secondary Objective	Secondary aims include correlating alterations in clinical and biological characteristics with disease status, and identifying genetic variants that predict disease progression or response to therapy.	2019-2035

Collaborators and Investigators

• Sponsor: University of California, San Francisco
• Collaborators: UCB Pharma
• Investigators: Principal Investigator: Haley B Naik, MD, MHSc, FAAD, University of California, San Francisco

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2020
• Primary Completion (Estimated): May 1, 2035
• Study Completion (Estimated): May 1, 2035

Study Registration Dates

• First Submitted: September 18, 2019
• First Submitted That Met QC Criteria: October 1, 2019
• First Posted (Actual): October 4, 2019

Study Record Updates

• Last Update Posted (Actual): April 29, 2026
• Last Update Submitted That Met QC Criteria: April 28, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Skin Diseases; Bacterial Infections; Bacterial Infections and Mycoses; Sweat Gland Diseases; Skin Diseases, Bacterial; Skin Diseases, Infectious; Suppuration; Hidradenitis; Skin and Connective Tissue Diseases; Hidradenitis Suppurativa
• Other Study ID Numbers: 18-27002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No